Who we are
Orexo is a commercial-stage pharmaceutical company with an international footprint. We are passionate about improving people's lives by offering innovative treatment solutions. Today, we develop pharmaceuticals based on proprietary drug delivery technologies, the same vision as when it all started in Uppsala, Sweden, 30 years ago.
History
Orexo was founded in 1995 in Uppsala, Sweden, with the vision of developing improved pharmaceuticals targeting large unmet needs among patients and caregivers. Thanks to proprietary drug delivery technologies, the company has successfully developed four products that have achieved global approval.
Commitment
We take advantage of every opportunity to use our international presence as a pharmaceutical company to enhance people's lives. Our primary focus is to alleviate the profound human suffering that opioid misuse can cause. We are also exploring other therapeutic areas where our innovative formulation technologies can improve pharmaceuticals for patients and healthcare professionals globally.
Approach
We develop improved pharmaceuticals by combining well-known APIs with proprietary drug delivery technologies. Our next generation drug delivery platform, AmorphOX®, is a world-class powder-based technology enabling outstanding bio-availability and stability of both small and large molecules.
We specialize in the commercialization of drugs and digital mental health programs for patients with opioid use disorder in the US. For products aimed at other therapeutic areas, we engage in collaborations with partners for both development and commercialization.
Team
Orexo should be an energizing and collaborative place to work at. Here, everyone’s valued for who they are as well as the contribution they make. We foster a culture of mutual respect so that individuals and teams can fulfill their potential in an inclusive, dynamic and inspiring environment.
Orexo is committed to the UN Global Compact corporate responsibility initative and its principles in the areas of human rights, labor, environment and anti-curroption. Read more on www.unglobalcompact.org.
>90%
of revenues in 2023 related to SDG 3.5*
*Target 3.5, Prevent and treat substance abuse